Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 Combined with Camrelizumab in BCG-Failed NMIBC
NCT05564897Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of Oncorine in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
Oncorine
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05564897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564897.